← Eichor
Condition: Ovarian Cancer Stage Iii Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ovarian Cancer Stage Iii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Phase 3 · 11 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT05737303Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemothera
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT04997096MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3 · 53 location(s) · Swiss GO Trial Group · NCT04111978Early Detection of Endometrial/Ovarian Cancer and Hereditary Predisposition of These Cancers
NA · 2 location(s) · McGill University · NCT04891029Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Can
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07144826The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
NA · 2 location(s) · University of Colorado, Boulder · NCT07636200AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Can
Phase 3 · 299 location(s) · AstraZeneca · NCT07218809CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Perito
Phase 3 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06834672Prehabilitation in Gynaecological Cancer Patients
Phase 3 · 1 location(s) · Charles University, Czech Republic · NCT04789694Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
Phase 3 · 19 location(s) · Ente Ospedaliero Ospedali Galliera · NCT05601700Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
Phase 2 · 8 location(s) · University Hospital, Linkoeping · NCT05284552Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 · 10 location(s) · Epitopea Ltd · NCT07665515An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV
NA · 1 location(s) · Roswell Park Cancer Institute · NCT06855706Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Phase 3 · 65 location(s) · AGO Study Group · NCT05009082A Study of Intra-operative Imaging in Women With Ovarian Cancer
Phase 3 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT04878094Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel i
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092373A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent
Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06994195MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurre
Phase 3 · 1 location(s) · National Cancer Institute, Naples · NCT05255471Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy
Phase 2 · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT03275194Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal
Phase 3 · 19 location(s) · M.D. Anderson Cancer Center · NCT04575935Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05415709Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer
NA · 1 location(s) · Yonsei University · NCT05444270Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
Phase 2 · 1 location(s) · University of Alabama at Birmingham · NCT05952453Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Phase 3 · 1 location(s) · Chipscreen Biosciences, Ltd. · NCT04921527CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery i
Phase 1/Phase 2 · 7 location(s) · TORL Biotherapeutics, LLC · NCT07322094A Study of SHR-A1811 in Subjects With Ovarian Cancer
Phase 3 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06828354Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targete
NA · 1 location(s) · The First Hospital of Jilin University · NCT07495397Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithe
Phase N/A · 1 location(s) · Gynecologic Oncology Group · NCT01000259
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.